Preparing for phase II/III HIV vaccine trials in Africa

Microbes and Infection

Volumn 7, Issue 14, 2005, Pages 1436-1444

  Vardas, Eftyhia ^a   Buttò, Stefano ^b   Glashoff, Richard ^c   Malnati, Mauro S ^d   Poli, Guido ^e   Clerici, Mario ^f  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Unit of Human Virology   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Cross reactivity; Sub Saharan Africa; Vaccine

Indexed keywords

ENVELOPE PROTEIN; GAMMA INTERFERON; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; NEF PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AMINO ACID SEQUENCE; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN RECOGNITION; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CLADISTICS; CLINICAL TRIAL; COMPETENCE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNOLOGY; GOOD CLINICAL PRACTICE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PATIENT COUNSELING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; SEXUAL BEHAVIOR; STANDARDIZATION; VIRUS REPLICATION;

ALPHAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 27844603848     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2005.07.021     Document Type: Short Survey

References (38)

1. UNAIDS Report on the global HIV/AIDS epidemic 2003 UNAIDS Geneva (UNAIDS 2003)
2. National HIV and syphilis antenatal sero-prevalence survey in South Africa - 2003. South African Department of Health, Directorate Health Systems Research, Research Coordination and Epidemiology (2004).
3. Operational Plan for Comprehensive HIV and AIDS Care, Management and Treatment for South Africa. South African Department of Health (November 2003).
4. C. Beyrer, and J.L. Excler Human immunodeficiency virus vaccine development in developing countries. Are efficacy trials feasible? J. Hum. Virol. 3 2000 193 214
5. E. Vardas E, M. Mogale, M. Maketla, A. Mafokhola, M. Mntambo, and G. Gray The HIV vaccine community outreach programme and the establishment of a dedicated vaccine Community Advisory Board (CAB) in Soweto, South Africa. International AIDS Conference 2002 Poster Number ThPeD7712 Barcelona
6. E. Vardas, and C. Slack Getting HIV vaccine trials started in Soweto Continuing Medical Education 20 2002 593 594
7. P. Kaleebu Experiences and results of Uganda's first HIV vaccine trial and preparations for the second. Retroviruses of human AIDS and related animal viruses 2002 XIII Cent Gardes Symposium Paris (November)
8. E. Vardas, S. Mayaphi, T. Mashego, M. Mogale, J. McIntyre, M. Molapo-Matsoso, V. Khambule, and G. Gray Cohort Enrollment and Maintenance for Phase I/II HIV Vaccine Trial Participants at the Perinatal HIV Research Unit (PHRU), in Soweto 2004 South Africa International AIDS Conference Bangkok
9. Z. Bentwich, A. Kalinovich, and Z. Weisman Immune activation is a dominant factor in the pathogenesis of African AIDS Immunol. Today 16 1995 187 191
10. P.L. Fleming, P.M. Wortley, J.M. Karon, K.M. DeCock, and R.S. Janssen Tracking the HIV epidemic: current issues, future challenges Am. J. Public Health 90 2000 1037 1041
11. R.S. Janssen, G.A. Satten, S.L. Stramer, B.D. Rawal, T.R. O'Brien, B.J. Weiblen, F.M. Hecht, N. Jack, F.R. Cleghorn, J.O. Kahn, M.A. Chesney, and M.P. Busch New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes JAMA 280 1998 42 48
12. B. Parekh, C.-P. Pau, S. Kennedy, T.L. Bobbs, and J.S. McDougal Assessment of antibody assays for identifying and distinguishing recent from long term HIV type 1 infection AIDS Res. Hum. Retroviruses 17 2001 137 146
13. B. Suligoi, C. Galli, M. Massi, F. Di Sora, M. Sciandra, P. Pezzotti, O. Recchia, F. Montella, A. Sinicco, and G. Rezza Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay based method J. Clin. Microbiol. 40 2002 4015 4020
14. G. Rizzardini, S. Piconi, S. Ruzzante, M.L. Fusi, M. Lukwiya, S. Declich, M.L. Villa, and M. Clerici Immunologic activation markers in the serum of African and Europeans HIV seropositive and seronegative individuals AIDS 10 1996 1535 1542
15. G. Rizzardini, D. Trabattoni, M. Saresella, S. Piconi, M. Lukwiya, S. Declich, P. Ferrante, and M. Clerici Immune activation in HIV-infected African individuals AIDS 12 1998 2387 2396
16. M. Clerici, S. Buttò, M. Lukwiya, S. Declich, D. Trabattoni, S. Piconi, P. Ferrante, G. Rizzardini, and L. Lopalco Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5 AIDS 14 2000 2083 2092
17. S.A. Koester, L. Matu, P. Kiama, O. Anzala, J. Embree, F.A. Plummer, J. Kimani, and K.R. Fowke Elevation of immune activation in Kenyan women is associated with alterations in immune function: implications for vaccine development J. Clin. Immunol. 24 2004 702 709
18. A. Abebe, D. Demissie, J. Goudsmit, M. Brouwer, C.L. Kuiken, G. Pollakis, H. Schuitemaker, A.L. Fontanet, and T.F. Rinke de Wit HIV-1 subtype C syncytium- and non syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS AIDS 13 1999 1305 1312
19. M.A. Papathanasopoulos, G.M. Hunt, and C.T. Tiemessen Evolution and diversity of HIV-1 in Africa-a review Virus Genes 26 2003 151 163
20. T.J. Tucker, and G. Mazithulela Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative BMJ 329 2004 454 456
21. A.L. Williamson The development of HIV-1 subtype C vaccines for Southern Africa IUBMB Life 53 2002 207 208
22. T.J. Scriba, J. zur Megede, R.H. Glashoff, F.K. Treurnicht, S.W. Barnett, and E. Janse van Rensburg Functionally inactive Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences Vaccine 23 2005 1158 1169
23. S. Buttò, V. Fiorelli, A. Tripiciano, M.J. Ruiz-Alvarez, A. Scoglio, F. Ensoli, M. Ciccozzi, B. Collacchi, M. Sabbatucci, A. Cafaro, C.A. Guzmán, A. Borsetti, A. Caputo, E. Vardas, M. Colvin, M. Lukwyia, G. Rezza, and B. Ensoli The Tat Multicentric Study Group, Cross-recognition of the Clade B HIV-1 Tat protein vaccine candidate by antibodies from HIV-1-infected Italian, Ugandan and South African individuals J. Infect. Dis. 188 2003 1171 1180
24. D.H. Barouch, S. Santra, J.E. Schmitz, M.J. Kuroda, T.M. Fu, W. Wagner, M. Bilska, A. Craiu, X.X. Zheng, G.R. Krivulka, K. Beaudry, M.A. Lifton, C.E. Nickerson, W.L. Trigona, K. Punt, D.C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M.E. Davies, M. Chastain, T.B. Strom, R.S. Gelman, D.C. Montefiori, M.G. Lewis, E.A. Emini, J.W. Shiver, and N.L. Letvin Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination Science 290 2000 486 492
25. L. Musey, J. Hughes, T. Schacker, T. Shea, L. Corey, and M.J. McElrath Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection N. Engl. J. Med. 337 1997 1267 1273
26. G.S. Ogg, X. Jin, S. Bonhoeffer, P.R. Dunbar, M.A. Nowak, S. Monard, J.P. Segal, Y. Cao, S.L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D.D. Ho, D.F. Nixon, and A.J. McMichael Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA Science 279 1998 2103 2106
27. A. Schmittel, U. Keilholz, and C. Scheibenbogen Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood J. Immunol. Methods 210 1997 167 174
28. M.R. Betts, D.R. Ambrozak, D.C. Douek, S. Bonhoeffer, J.M. Brenchley, J.P. Casazza, R.A. Koup, and L.J. Picker Analysis of total human immunodeficiency virus (HIV)-specific CD4 and CD8 T-cell responses: relationship to viral load in untreated HIV infection J. Virol. 75 2001 11983 11991
29. B. Gaschen, J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B.H. Hahn, T. Bhattacharya, and B. Korber Diversity considerations in HIV-1 vaccine selection Science 296 2002 2354 2360
30. A.J. McMichael, and R.E. Phillips Escape of HIV from immune control Annu. Rev. Immunol. 15 1997 271 296
31. R. Draenert, M. Altfeld, C. Brander, N. Basgoz, C. Corcoran, A.G. Wurcel, D.R. Stone, S.A. Kalams, A. Trocha, M.M. Addo, P.J. Goulder, and B.D. Walker Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses J. Immunol. Methods 275 2003 19 29
32. M. Altfeld, M.M. Addo, R. Shankarappa, P.K. Lee, M.A. Allen, X.G. Yu, A. Rathod, J. Harlow, K. O'Sullivan, M.N. Johnston, P.J.R. Goulder, J.I. Mullins, E.S. Rosemberg, C. Brander, B. Korber, and B.D. Walker Enhance detection of human immunodeficiency virus Type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences J. Virol. 77 2003 7330 7340
33. A.S. De Groot, B. Jesdale, W. Martin, C. Saint Aubin, H. Sbai, A. Bosma, J. Lieberman, G. Skowrond, F. Mansourati, and K.H. Mayer Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach Vaccine 21 2003 4486 4504
34. T. Beattie, R. Kaulb, T. Rostron, T. Dong, P. Easterbrook, W. Jaokod, J. Kimanid, F. Plummere, A. McMichael, and S. Rowland-Jones Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes AIDS 18 2004 1595 1606
35. R. Kaul, T. Dong, F.A. Plummer, J. Kimani, T. Rostron, P. Kiama, E. Njagi, R. Chakraborty, E. Irungu, J. Oyugi, K.S. MacDonald, J.J. Bwayo, A. McMichael, and S.L. Rowland-Jones CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects J. Clin. Invest. 107 2001 1303 1310
36. N.D. Russell, M.G. Hudgens, R. Ha, C. Havenar-Daughton, and M.J. McElrath Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity J. Infect. Dis. 187 2003 226 242
37. T.U. Vogel, H. Horton, D.H. Fuller, D.K. Carter, K. Vielhuber, D.H. O'Connor, T. Shipley, J. Fuller, G. Sutter, V. Erfle, N. Wilson, L.J. Picker, and D.I. Watkins Differences between T cell epitopes recognized after immunization and after infection J. Immunol. 169 2002 4511 4521
38. R. Draenert, C. Brandera, X.G. Yua, M. Altfeld, C.L. Verrilla, M.E. Feeneya, B.D. Walker, and P.J.R. Goulder Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels AIDS 18 2004 871 876